Teresa Harris Graham, CEO of Roche Pharmaceuticals, shared on LinkedIn:
“We are living through an era of unprecedented scientific breakthroughs. The tools at our disposal to stop, prevent, and cure chronic diseases are advancing exponentially. These breakthroughs have the power to transform health care systems and the lives of the people they serve.
The question for treasuries across Europe is no longer whether we can afford to invest in these rapid advances. The real and urgent question is:
Can we survive the economic cost of hesitation?
We know that treating HER2-positive breast cancer with targeted therapies in a single year generated €1.7 billion in societal and economic value across ten major economies. Why?
Because patients were treated early enough to return to work. To their families. To their lives.
Sustainable fiscal policy doesn’t mean cutting healthcare spending; it means investing early to unlock long-term economic productivity. One patient at a time.”
